Antithrombotic Therapy in Peripheral Arterial Occlusive Disease
Copyright policy )Antithrombotic Therapy in Peripheral Arterial Occlusive Disease
Abbreviations: ACD 5 absolute claudication distance; CI 5 confidence interval; INR 5 international normalized ratio; LMWH 5 low-molecular-weight heparin; MI 5 myocardial infarction; NASCET 5 North American Symptomatic Carotid Endarterectomy Trial; PGE1 5 prostaglandin E1; PGI2 5 prostaglandin I2; PTFE 5 polytetrafluoroethylene; rtPA 5 recombinant tissue plasminogen activator; tPA 5 tissue plasminogen activator; UFH 5 unfractionated heparin (CHEST 2001; 119:283S–299S)
- The University of Texas Southwestern Medical Center United States
Peripheral Vascular Diseases, Fibrinolytic Agents, Anticoagulants, Humans, Arterial Occlusive Diseases, Thrombolytic Therapy, Vascular Surgical Procedures, Platelet Aggregation Inhibitors
Peripheral Vascular Diseases, Fibrinolytic Agents, Anticoagulants, Humans, Arterial Occlusive Diseases, Thrombolytic Therapy, Vascular Surgical Procedures, Platelet Aggregation Inhibitors
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).33 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!